CN114487437A - 一种胶乳免疫比浊法测定白介素23的试剂盒 - Google Patents
一种胶乳免疫比浊法测定白介素23的试剂盒 Download PDFInfo
- Publication number
- CN114487437A CN114487437A CN202210075290.0A CN202210075290A CN114487437A CN 114487437 A CN114487437 A CN 114487437A CN 202210075290 A CN202210075290 A CN 202210075290A CN 114487437 A CN114487437 A CN 114487437A
- Authority
- CN
- China
- Prior art keywords
- interleukin
- kit
- buffer solution
- latex
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010065637 Interleukin-23 Proteins 0.000 title claims abstract description 57
- 102000013264 Interleukin-23 Human genes 0.000 title claims abstract description 57
- 229940124829 interleukin-23 Drugs 0.000 title claims abstract description 47
- 239000004816 latex Substances 0.000 title claims abstract description 42
- 229920000126 latex Polymers 0.000 title claims abstract description 42
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000007853 buffer solution Substances 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 17
- 239000003381 stabilizer Substances 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000007987 MES buffer Substances 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 4
- 239000000701 coagulant Substances 0.000 claims description 4
- -1 polyoxyethylene lauryl ether Polymers 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 3
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 claims description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003508 Dilauryl thiodipropionate Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 230000021523 carboxylation Effects 0.000 claims description 3
- 238000006473 carboxylation reaction Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 3
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- ZTOKUMPYMPKCFX-CZNUEWPDSA-N (E)-17-[(2R,3R,4S,5S,6R)-6-(acetyloxymethyl)-3-[(2S,3R,4S,5S,6R)-6-(acetyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxyoctadec-9-enoic acid Chemical compound OC(=O)CCCCCCC/C=C/CCCCCCC(C)O[C@@H]1O[C@H](COC(C)=O)[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(C)=O)O1 ZTOKUMPYMPKCFX-CZNUEWPDSA-N 0.000 claims description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 239000002211 L-ascorbic acid Substances 0.000 claims description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004353 Polyethylene glycol 8000 Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 229940125717 barbiturate Drugs 0.000 claims description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 229940085678 polyethylene glycol 8000 Drugs 0.000 claims description 2
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 claims description 2
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 229940074410 trehalose Drugs 0.000 claims description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical class [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 2
- MCHZKGNHFPNZDP-UHFFFAOYSA-N 2-aminoethane-1,1,1-triol;hydrochloride Chemical compound Cl.NCC(O)(O)O MCHZKGNHFPNZDP-UHFFFAOYSA-N 0.000 claims 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 16
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 238000005259 measurement Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 210000000068 Th17 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- CWGFSQJQIHRAAE-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.OCC(N)(CO)CO CWGFSQJQIHRAAE-UHFFFAOYSA-N 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种胶乳免疫比浊法测定白介素23的试剂盒包含试剂R1、试剂R2和白介素23校准品,该试剂盒说明简单、易操作,能够直接采用全自动生化分析仪进行样本检测,能满足临床实验室高通量快速检测样本的需求,同时可减少人为误差使检验效率明显提高;试剂盒采用胶乳免疫比浊法,使得试剂稳定性有进一步提高,通常在2‑8℃环境下可稳定存放一年及以上,因此在临床上有较大的应用空间,可广泛推广应用大多数临床实验室。
Description
技术领域
本发明属于体外诊断试剂技术领域,尤其涉及一种胶乳免疫比浊法测定白介素23的试剂盒。
背景技术
白介素23(IL-23)是Oppmann等人于2000年发现的白介素12(IL-12)细胞因子家族的一个新成员。它与IL-12一样,都是含有亚单位p40和IL-12R1受体的异源二聚体细胞因子,它们的功能部分重叠而又有所不同。IL-23是一个由亚单位p19和p40通过二硫键形成的异源二聚体分子,结构为p19/p40,任何一个单独的亚单位都不具有生物学活性,只有2个亚单位结合在一起时,才能发挥它的生物功能。作为IL-12家族的新成员,IL-23主要作为一种促炎症细胞因子而发挥作用,它作用于记忆性T细胞,具有影响免疫反应的作用,还具有潜在的抗肿瘤、抗感染作用。过去认为IL-12是某些疾病的作用因子,而现在则认为IL-23才是真正的作用因子。
IL-23主要通过与其受体相互作用,激活下游信号通路发挥生物学功能。
IL-23主要作用于Th17细胞,在Th17细胞的增殖与稳定中发挥重要作用,并能促进Th17细胞产生IL-23、IL-17F及IL-22等细胞因子,这些炎症因子作用于角质形成细胞,导致角质形成细胞活化和过度增殖。活化的角质形成细胞又通过产生大量细胞因子、趋化因子和抗菌肽等,募集并激活T细胞等免疫细胞,形成免疫应答的级联效应,引起银屑病损害的发生。IL-23在关节自身免疫炎症中,也是一个促进因子,如在风湿性关节炎中,IL-23促进IL—17的分泌,从而导致了关节的破坏。因此血液中IL-23的检测及其水平变化就显得尤为重要,
现有的白介素23的检测试剂盒较少,而且价格昂贵,传统的酶联免疫检测白介素23的(ELISA)方法,该方法虽较为传统,应用较为普遍,但测定过程操作繁琐、操作时间长、自动化程度低、重复性和批间差相对较大,不能适应大体量样本的筛查,且该方法应用时需配备多种专用设备,在一定程度上也增加使用成本。
为了解决现有技术中存在的以上问题,我们提出一种胶乳免疫比浊法测定白介素23的试剂盒。
发明内容
本发明的目的在于提供一种胶乳免疫比浊法测定白介素23的试剂盒。,其操作简便快捷、检测稳定性和重复性好、可应用于全自动生化仪,实现自动化操作和自动化分析、且使用成本相对降低,从而弥补上述背景技术中的不足。
为实现上述目的,本发明提供如下技术方案:一种胶乳免疫比浊法测定白介素23的试剂盒包含试剂R1、试剂R2和白介素23校准品,其中,
所述试剂R1包括:缓冲液10~500mmol/L、稳定剂10.1~10g/L、稳定剂20.1~10g/L、无机盐1~50g/L、表面活性剂0.5~50g/L、促凝剂1~100g/L、抗氧化剂0.01~10g/L、防腐剂0.5~10g/L,pH值为6.0~9.0;
所述试剂R2包括:缓冲液10~500mmol/L、抗人白介素23抗体包被胶乳颗粒5~500mg/L、表面活性剂0.5~50g/L、稳定剂10.1~10g/L、稳定剂20.1~10g/L、无机盐1~50g/L、抗氧化剂0.01~10g/L、防腐剂0.5~10g/L,pH值为6.0~9.0;
所述白介素23校准品包括:缓冲液10~500mmol/L、抗人白介素23抗原100-500ng/mL、稳定剂0.1~10g/L、抗氧化剂0.01~10g/L、防腐剂0.5~10g/L,pH值为6.0~9.0。
优选的,所述缓冲液选自三羟甲基氨基甲烷-盐酸(Tris-HCL)缓冲液、3-吗啉丙磺酸(MOPS)缓冲液、4-羟乙基哌嗪乙磺酸(HEPES)缓冲液、哌嗪-1,4-二乙磺酸(PIPES)缓冲液、2-(N-吗啉代)乙磺酸(MES)缓冲液、3-(环己氨基)2-羟基-1-丙磺酸(CAPSO)缓冲液、甘氨酸缓冲液、柠檬酸缓冲液、巴比妥钠缓冲液、硼酸缓冲液、磷酸盐缓冲液中的一种或几种。
优选的,所述稳定剂1和稳定剂2选自乙二胺四乙酸二钠、牛血清白蛋白、山梨醇、葡萄糖、海藻糖中的一种或几种;
所述无机盐选自氯化钠、氯化钾、氯化镁、硫酸镁中的一种或几种。
优选的,所述表面活性剂选自Tween系列、Triton系列、月桂醇聚氧乙烯醚(Brij-35)、脂肪醇聚氧乙烯醚(AEO)、槐糖脂中的一种或几种;
优选的,所述促凝剂选自聚乙二醇6000、聚乙二醇8000、聚乙二醇20000中的一种或几种;
优选的,所述防腐剂选自叠氮钠、proclin300、硫柳汞钠、苯酚、尼泊金乙酯中的一种或几种;
优选的,所述抗人白介素23抗体选自羊抗人、鼠抗人、兔抗人抗体中的一种。
优选的,所述抗氧化剂选自L-抗坏血酸、硫代二丙酸二月桂酯(DLTP)、2,6二叔丁基对甲酚(BHT)、丁基羟基茴香醚(BHA)、二丁基羟基甲苯(BHT)、特丁基对苯二酚(TBHQ)中的一种或几种。
优选的,所述试剂盒包括以下组分,
所述试剂R1:pH值为7~8
所述试剂R2:pH值为6~8
所述白介素23校准品:pH值为7.5
优选的,所述抗人白介素23抗体包被胶乳颗粒的制备方法为:取1ml~2ml表面羧基化、直径200nm的聚苯乙烯胶乳溶液加入到10ml的MES缓冲液中,使胶乳颗粒终浓度为1.0%;然后加入0.1~1mg抗人白介素23抗体抗体以及活化剂1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC),在37℃孵育2-4小时,通过活化的羧基与胶乳颗粒溶液进行化学交联,形成共价抗体胶乳复合物;然后,加入适量的0.1%的BSA溶液在37℃条件下封闭0.5~2小时,封闭胶乳颗粒表面未结合抗体的表面活性基团,再以12000rpm离心30~50分钟,去除上清,所得沉淀加入含0.1%BSA的50mmol/L的Tris-HCl缓冲液洗涤、分散即得抗人白介素23抗体包被胶乳颗粒。
与现有技术相比,本发明的有益效果是:与现有的检测技术相比较,本发明提供的抗人白介素23抗体检测试剂盒说明简单、易操作,能够直接采用全自动生化分析仪进行样本检测,能满足临床实验室高通量快速检测样本的需求,同时可减少人为误差使检验效率明显提高;试剂盒采用胶乳免疫比浊法,使得试剂稳定性有进一步提高,通常在2-8℃环境下可稳定存放一年及以上,因此在临床上有较大的应用空间,可广泛推广应用大多数临床实验室。
具体实施方式
除有明确定义外,以下实施例中所用的技术术语与本发明所属领域技术人员普遍理解的含义相同。以下实施例中所用的实验试剂,如无特殊说明,均为常规生化试剂;所述实验方法,如无特殊说明,均为常规方法。
下面结合实施例来详细说明本发明。
1、具体实施例
实施例1:
试剂R1:pH值为7.4
试剂R2:pH为7.5
实施例2:
试剂R1:pH值为7.5
试剂R2:pH为7.5
实施例3:
试剂R1:pH为7.5
试剂R2:pH为7.5
实施例1-3的校准品均选用以下组分配方:校准品:PH7.5
将抗人白介素23抗原添加到上述校准品溶液中,制备得到抗人白介素23高浓度校准品,再用生理盐水稀释到不同浓度点。
实施例1-3均配制5个不同浓度的校准品,分别为:0ng/mL、6.25ng/mL、12.5ng/mL、25ng/mL、50ng/mL。
实际交付时可以带一个高值校准品,客户按说明自己倍比稀释;也可以配制多个不同浓度的校准品直接放在试剂盒里,用校准品这6个点做校准曲线,实例中测值是仪器测试样品在校准曲线上计算得出。
上述实施例1-3所提到的抗人白介素23抗体包被胶乳颗粒的制备方法为:取适量的表面羧基化、直径200nm的聚苯乙烯胶乳溶液加入到10ml的MES缓冲液中,使胶乳颗粒终浓度为1.0%;然后加入适量抗人白介素23抗体抗体以及活化剂1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC),在37℃孵育3小时左右,通过活化的羧基与胶乳颗粒溶液进行化学交联,形成共价抗体胶乳复合物。然后,加入适量的0.1%的BSA溶液在37℃条件下封闭1小时,封闭胶乳颗粒表面未结合抗体的表面活性基团,再以12000rpm离心40分钟,去除上清,所得沉淀加入含0.1%BSA的50mmol/L Tris-HCl缓冲液洗涤、分散即得抗人白介素23抗体包被胶乳颗粒。
2、检测方法
以上实施例所述试剂盒,在使用时,其测定方法均是采用佳能TBA-120FR全自动生化分析仪,利用终点法进行测定,检测主波长为450nm,操作程序如表1:
表1试剂盒检测方法
3、结果计算
抗人白介素23含量(ng/mL)=(ΔA样本/ΔA校准品)×校准品浓度。
4、性能验证
4.1重复性和准确度:
以各实例的校准品和标示值为15ng/ml的人血清作为样本,对各实例中的试剂盒进行重复性考察,按要求测定方法分别重复测定10次,分别计算测定平均值X、标准偏差SD及变异系数CV,以对各实例中的试剂盒进行重复性进行考察,测定结果见表2。
表2试剂盒重复性测定结果
根据表2结果可以看出,实例1、实例2、实例3的CV均<5%。
以各实施例的校准品和试剂盒与对照试剂盒(市售某厂家的酶联免疫法抗人白介素23检测试剂盒,简称“ELISA试剂盒”)同时测试检测40个正常人血清样本,统计检测结果,计算两者的相关系数,并进行线性回归,对检测结果进行相关性分析,以对各实例中的试剂盒进行准确度考察,测定结果见表3。
表3试剂盒准确度测定结果
根据表3结果可以看出,实例1、实例2、实例3的相关系数均小于0.975,说明本发明各实例的试剂盒具有较高的准确性。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (10)
1.一种胶乳免疫比浊法测定白介素23的试剂盒,其特征在于:所述试剂盒包含试剂R1、试剂R2和白介素23校准品,其中,
所述试剂R1包括:缓冲液10~500mmol/L、稳定剂10.1~10g/L、稳定剂20.1~10g/L、无机盐1~50g/L、表面活性剂0.5~50g/L、促凝剂1~100g/L、抗氧化剂0.01~10g/L、防腐剂0.5~10g/L,pH值为6.0~9.0;
所述试剂R2包括:缓冲液10~500mmol/L、抗人白介素23抗体包被胶乳颗粒5~500mg/L、表面活性剂0.5~50g/L、稳定剂10.1~10g/L、稳定剂20.1~10g/L、无机盐1~50g/L、抗氧化剂0.01~10g/L、防腐剂0.5~10g/L,pH值为6.0~9.0;
所述白介素23校准品包括:缓冲液10~500mmol/L、抗人白介素23抗原100-500ng/mL、稳定剂0.1~10g/L、抗氧化剂0.01~10g/L、防腐剂0.5~10g/L,pH值为6.0~9.0。
2.根据权利要求1所述的胶乳免疫比浊法测定白介素23的试剂盒,其特征在于:所述缓冲液选自三羟甲基氨基甲烷-盐酸缓冲液、3-吗啉丙磺酸缓冲液、4-羟乙基哌嗪乙磺酸缓冲液、哌嗪-1,4-二乙磺酸缓冲液、2-(N-吗啉代)乙磺酸缓冲液、3-(环己氨基)2-羟基-1-丙磺酸缓冲液、甘氨酸缓冲液、柠檬酸缓冲液、巴比妥钠缓冲液、硼酸缓冲液、磷酸盐缓冲液中的一种或几种。
3.根据权利要求1所述的胶乳免疫比浊法测定白介素23的试剂盒,其特征在于:所述稳定剂1和稳定剂2选自乙二胺四乙酸二钠、牛血清白蛋白、山梨醇、葡萄糖、海藻糖中的一种或几种。
所述无机盐选自氯化钠、氯化钾、氯化镁、硫酸镁中的一种或几种。
4.根据权利要求1所述的胶乳免疫比浊法测定白介素23的试剂盒,其特征在于:所述表面活性剂选自Tween系列、Triton系列、月桂醇聚氧乙烯醚、脂肪醇聚氧乙烯醚、槐糖脂中的一种或几种。
5.根据权利要求1所述的胶乳免疫比浊法测定白介素23的试剂盒,其特征在于:所述促凝剂选自聚乙二醇6000、聚乙二醇8000、聚乙二醇20000中的一种或几种。
6.根据权利要求1所述的胶乳免疫比浊法测定白介素23的试剂盒,其特征在于:所述防腐剂选自叠氮钠、proclin300、硫柳汞钠、苯酚、尼泊金乙酯中的一种或几种。
7.根据权利要求1所述的胶乳免疫比浊法测定白介素23的试剂盒,其特征在于:所述抗人白介素23抗体选自羊抗人、鼠抗人、兔抗人抗体中的一种。
8.根据权利要求1所述的胶乳免疫比浊法测定白介素23的试剂盒,其特征在于:所述抗氧化剂选自L-抗坏血酸、硫代二丙酸二月桂酯、2,6二叔丁基对甲酚、丁基羟基茴香醚、二丁基羟基甲苯、特丁基对苯二酚中的一种或几种。
10.根据权利要求1所述的胶乳免疫比浊法测定白介素23的试剂盒,其特征在于:所述抗人白介素23抗体包被胶乳颗粒的制备方法为:取1ml~2ml表面羧基化、直径200nm的聚苯乙烯胶乳溶液加入到10ml的MES缓冲液中,使胶乳颗粒终浓度为1.0%;然后加入0.1~1mg抗人白介素23抗体抗体以及活化剂1-乙基-(3-二甲基氨基丙基)碳酰二亚胺,在37℃孵育2-4小时,通过活化的羧基与胶乳颗粒溶液进行化学交联,形成共价抗体胶乳复合物;然后,加入适量的0.1%的BSA溶液在37℃条件下封闭0.5~2小时,封闭胶乳颗粒表面未结合抗体的表面活性基团,再以12000rpm离心30~50分钟,去除上清,所得沉淀加入含0.1%BSA的50mmol/L的Tris-HCl缓冲液洗涤、分散即得抗人白介素23抗体包被胶乳颗粒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210075290.0A CN114487437A (zh) | 2022-01-22 | 2022-01-22 | 一种胶乳免疫比浊法测定白介素23的试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210075290.0A CN114487437A (zh) | 2022-01-22 | 2022-01-22 | 一种胶乳免疫比浊法测定白介素23的试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114487437A true CN114487437A (zh) | 2022-05-13 |
Family
ID=81471720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210075290.0A Pending CN114487437A (zh) | 2022-01-22 | 2022-01-22 | 一种胶乳免疫比浊法测定白介素23的试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114487437A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102944673A (zh) * | 2012-11-30 | 2013-02-27 | 北京华宇亿康生物工程技术有限公司 | 一种用于检测血清中甘胆酸含量的试剂盒(胶乳增强免疫比浊法) |
CN110794131A (zh) * | 2019-09-12 | 2020-02-14 | 苏州普瑞斯生物科技有限公司 | 一种白介素-6检测试剂盒及其制备方法 |
WO2021248718A1 (zh) * | 2020-06-12 | 2021-12-16 | 江苏荃信生物医药股份有限公司 | 抗人白介素23单克隆抗体及其应用 |
-
2022
- 2022-01-22 CN CN202210075290.0A patent/CN114487437A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102944673A (zh) * | 2012-11-30 | 2013-02-27 | 北京华宇亿康生物工程技术有限公司 | 一种用于检测血清中甘胆酸含量的试剂盒(胶乳增强免疫比浊法) |
CN110794131A (zh) * | 2019-09-12 | 2020-02-14 | 苏州普瑞斯生物科技有限公司 | 一种白介素-6检测试剂盒及其制备方法 |
WO2021248718A1 (zh) * | 2020-06-12 | 2021-12-16 | 江苏荃信生物医药股份有限公司 | 抗人白介素23单克隆抗体及其应用 |
Non-Patent Citations (2)
Title |
---|
张国华等: "类风湿关节炎患者外周血白细胞介素-23和类风湿因子的表达研究", 中国医药导报, no. 18, 25 June 2011 (2011-06-25), pages 23 - 24 * |
薛冰等: "血清IFN-γ、IL-4、IL-12、IL-23对肺结核免疫的作用研究", 新疆医科大学学报, no. 03, 15 March 2017 (2017-03-15), pages 341 - 344 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220163534A1 (en) | Kit for detecting soluble growth stimulation expressed gene 2 protein | |
CN110687286A (zh) | 胶乳增强免疫比浊法试剂盒 | |
Delhaes et al. | Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: State of the art and further challenges | |
CN112014577B (zh) | 一种提高gpc3检测灵敏度的试剂盒及其制备方法 | |
Berthier et al. | Evaluation of an Automated Method for Cytokine Measurement Using the Immulite® Immunoassay System | |
CN113156139A (zh) | 测定实验对象组 | |
WO2022100077A1 (zh) | 一种灵敏度高的抗Ro52抗体检测试剂盒 | |
CN113804896A (zh) | 测定人体血清中白介素-8含量的磁微粒化学发光试剂盒 | |
CN111239414A (zh) | 一种检测il-6的试剂盒及检测il-6的方法 | |
CN117607459B (zh) | 一种中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒及其制备方法和应用 | |
CN112858698B (zh) | 一种d-二聚体胶乳增强免疫比浊试剂盒及其制备方法 | |
CN108362892B (zh) | 一种降钙素原胶体金免疫比浊法检测试剂 | |
CN117434274A (zh) | 一种单人份白介素6磁微粒化学发光试剂盒及其测定方法 | |
EP3480601B1 (en) | Inhibin b chemiluminescent immunoassay kit and preparation method therefor | |
CN111239404B (zh) | 一种可以同时检测尿样本和血清样本中的视黄醇结合蛋白的检测试剂盒 | |
CN114487437A (zh) | 一种胶乳免疫比浊法测定白介素23的试剂盒 | |
CN117330759A (zh) | 检测肿瘤伴随诊断相关因子的试剂盒及其检测方法 | |
CN115856320A (zh) | 一种稳定性好的抗原检测试剂盒及其应用 | |
CN115267195A (zh) | 一种胸苷激酶1磁微粒化学发光检测试剂 | |
CN116183931A (zh) | 一种半乳糖凝集素-3磁微粒化学发光免疫定量检测试剂盒 | |
CN115561450A (zh) | 用于检测触珠蛋白含量的试剂盒 | |
CN115327137A (zh) | 一种人免疫球蛋白g4亚型化学发光免疫检测试剂盒 | |
CN112485447B (zh) | 一种测定补体C1q的试剂盒 | |
Hedayati et al. | Determination of human tumor necrosis factor α by a highly sensitive enzyme immunoassay | |
CN114295840A (zh) | 一种高灵敏度定量测定脂联素的试剂盒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |